Literature DB >> 6110504

Dose-response studies of indenolol, a beta adrenoceptor blocker.

F E Okupa, T K Daneshmend, E Shrosbree, C J Roberts.   

Abstract

Two studies were conducted on indenolol, a new beta-adrenoceptor blocker. In the first, nine healthy men received indenolol 40, 80, 160, and 320 mg and placebo orally. Two hours later a standard exercise test was performed, and systolic blood pressure, heart rate, and peak expiratory flow rate were recorded. Indenolol induced attenuation of exercise-induced rise in systolic blood pressure and tachycardia. In the second study, seven healthy men received indenolol 40, 80, 160, and 320 mg and propranolol 40, 80, 160, and 320 mg in randomized order. Dose-response curves for both drugs revealed that maximum attenuation of exercise tachycardia and systolic blood pressure were in the same range but suggested that indenolol induced a greater response in the lower doses. Neither drug had any effect on the exercise-induced rise in peak expiratory flow rate. Indenolol was well tolerated.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6110504     DOI: 10.1038/clpt.1981.60

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Acute effect of indenolol on human airways.

Authors:  P Zanon; C Bruschi; I Cerveri; A Rossi; P Karitinos; F Pamparana
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.

Authors:  A Wellstein; D Palm; H F Pitschner; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Acute and long-term haemodynamic effects of propranolol and indenolol in hypertension.

Authors:  E Malacco; F Mailland; E Bosisio; R Meroni; R Dagani; E Renesto; M Bevilacqua
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Beta-blockade antagonism of tyramine-induced rise in blood pressure.

Authors:  F Colombo; R Sega; F Mailland; R Rigo; L Palvarini; A Libretti
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.